Prospective phase II clinical trial of molecular glioblastoma (historical grade 2 and 3 IDH wildtype gliomas) preliminary novel exploratory analyses - Top-Institutions - MDSpire

Prospective phase II clinical trial of molecular glioblastoma (historical grade 2 and 3 IDH wildtype gliomas) preliminary novel exploratory analyses

  • By

  • Debra Nana Yeboa

  • Benjamin T. Whitfield

  • Ruitao Lin

  • Chinenye Lynette Ejezie

  • Todd A. Swanson

  • Thomas H. Beckham

  • Chenyang Wang

  • Brian De

  • Subha Perni

  • Martin C. Tom

  • Jing Li

  • Susan L. McGovern

  • Rebecca Harrison

  • Nazanin K. Majd

  • Vinay K. Puduvalli

  • Ashley E. Aaroe

  • Monica Loghin

  • Barbara J. O’Brien

  • Anuj D. Patel

  • Chirag B. Patel

  • Jeffrey S. Wefel

  • Ceylan Altintas Taslicay

  • Maria Gule-Monroe

  • Arnold C. Paulino

  • Mary Frances McAleer

  • David R. Grosshans

  • Amol J. Ghia

  • Wen Jiang

  • Caroline Chung

  • Moshe Maor

  • Cheng-Han Yang

  • Maria A. Gubbiotti

  • Carlos Kamiya-Matsuoka

  • Leomar Y. Ballester

  • Shiao-Pei Weathers

  • Jason T. Huse

  • November 5, 2025

  • 0 min

Share

Top Institutions in Oncology

Brief introduction explaining scope and methodology.

  • #1

    Memorial Sloan Kettering Cancer Center
    Memorial Sloan Kettering Cancer Center

    New York, NY

    Key Differentiators

    • Neuro-oncology
    • Molecular Oncology
    • Radiation Oncology

  • #2

    Dana-Farber Cancer Institute / Brigham and Women's Hospital / Harvard Medical School
    Dana-Farber Cancer Institute / Brigham and Women's Hospital / Harvard Medical School

    Boston, MA

    Key Differentiators

    • Neuro-oncology
    • Molecular Pathology
    • Radiation Oncology

  • #3

    MD Anderson Cancer Center
    MD Anderson Cancer Center

    Houston, TX

    Key Differentiators

    • Neuro-oncology
    • Radiation Oncology
    • Molecular Oncology

  • #4

    University of California, San Francisco (UCSF) Medical Center
    University of California, San Francisco (UCSF) Medical Center

    San Francisco, CA

    Key Differentiators

    • Neuro-oncology
    • Neuropathology
    • Radiation Oncology

  • #5

    Johns Hopkins Hospital
    Johns Hopkins Hospital

    Baltimore, MD

    Key Differentiators

    • Neuro-oncology
    • Neuropathology
    • Radiation Oncology

Original Source(s)

Prospective phase II clinical trial of molecular glioblastoma (historical grade 2 and 3 IDH wildtype gliomas) preliminary novel exploratory analyses

  • by Debra Nana Yeboa, Benjamin T. Whitfield, Ruitao Lin, Chinenye Lynette Ejezie, Todd A. Swanson, Thomas H. Beckham, Chenyang Wang, Brian De, Subha Perni, Martin C. Tom, Jing Li, Susan L. McGovern, Rebecca Harrison, Nazanin K. Majd, Vinay K. Puduvalli, Ashley E. Aaroe, Monica Loghin, Barbara J. O’Brien, Anuj D. Patel, Chirag B. Patel, Jeffrey S. Wefel, Ceylan Altintas Taslicay, Maria Gule-Monroe, Arnold C. Paulino, Mary Frances McAleer, David R. Grosshans, Amol J. Ghia, Wen Jiang, Caroline Chung, Moshe Maor, Cheng-Han Yang, Maria A. Gubbiotti, Carlos Kamiya-Matsuoka, Leomar Y. Ballester, Shiao-Pei Weathers, Jason T. Huse

  • November 5, 2025

Related Content

Characteristics and risk factors of immune-related adverse events in patients receiving immune checkpoint inhibitor combination therapy

Novel approaches for separating graft-versus-leukemia effects from graft-versus-host disease

Case Report: Synovial sarcoma with diffuse myxoid stroma and complete absence of epithelial differentiation in the extremity